NCT00501657

Brief Summary

The purpose of this study is to determine the effects of the drug, sitagliptin, on the rate at which the stomach empties, and the release of gut hormones and blood glucose concentrations, after a mashed potato meal in healthy subjects. Sitagliptin has been shown to reduce the blood glucose (sugar) response to a meal and this may potentially be due to slowing of stomach emptying. This is particularly relevant to people who have diabetes, in whom normalization of elevated blood glucose levels is important to maintain health.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
15

participants targeted

Target at below P25 for phase_1

Timeline
Completed

Started Jul 2007

Longer than P75 for phase_1

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2007

Completed
12 days until next milestone

First Submitted

Initial submission to the registry

July 13, 2007

Completed
3 days until next milestone

First Posted

Study publicly available on registry

July 16, 2007

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2008

Completed
3.5 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2011

Completed
Last Updated

October 29, 2015

Status Verified

December 1, 2014

Enrollment Period

11 months

First QC Date

July 13, 2007

Last Update Submit

October 27, 2015

Conditions

Keywords

gastric emptyingglycemiaappetiteincretin hormones

Outcome Measures

Primary Outcomes (1)

  • Gastric emptying rate

    4 hours per study

Secondary Outcomes (1)

  • Intragastric distribution, gastrointestinal hormone release (GLP-1, GIP), glycemia, insulinemia, appetite

    4 hours per study

Study Arms (2)

Sitagliptin (100mg)

EXPERIMENTAL

Active drug (sitagliptin)

Drug: Sitagliptin

Placebo (sugar pill)

PLACEBO COMPARATOR

Inactive drug (placebo)

Drug: Placebo

Interventions

100mg mane for 2 days

Also known as: MK-0431-075, Januvia
Sitagliptin (100mg)

100mg mane for 2 days

Placebo (sugar pill)

Eligibility Criteria

Age18 Years - 45 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Male or female (females must be using an appropriate contraceptive method)
  • years
  • Body mass index (BMI) 19 - 25 kg/m2.

You may not qualify if:

  • Subjects with gastrointestinal disease, history of gastrointestinal surgery and/or significant gastrointestinal symptoms
  • Subjects taking medication known to influence gastrointestinal function
  • Alcohol intake \> 20 g per day
  • Smoking \> 10 cigarettes per day
  • Pregnant and/or lactating females
  • Calculated creatinine clearance \< 60 ml/min
  • Exposure to ionising radiation for research purposes in the previous 12 months.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Discipline of Medicine, Royal Adelaide Hospital

Adelaide, South Australia, 5000, Australia

Location

Related Publications (1)

  • Stevens JE, Horowitz M, Deacon CF, Nauck M, Rayner CK, Jones KL. The effects of sitagliptin on gastric emptying in healthy humans - a randomised, controlled study. Aliment Pharmacol Ther. 2012 Aug;36(4):379-90. doi: 10.1111/j.1365-2036.2012.05198.x. Epub 2012 Jun 28.

Related Links

MeSH Terms

Conditions

GastroparesisDiabetes Mellitus

Interventions

Sitagliptin Phosphate

Condition Hierarchy (Ancestors)

Stomach DiseasesGastrointestinal DiseasesDigestive System DiseasesParalysisNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Intervention Hierarchy (Ancestors)

TriazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsPyrazines

Study Officials

  • Karen L Jones, PhD

    University of Adelaide, Royal Adelaide Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

July 13, 2007

First Posted

July 16, 2007

Study Start

July 1, 2007

Primary Completion

June 1, 2008

Study Completion

December 1, 2011

Last Updated

October 29, 2015

Record last verified: 2014-12

Locations